Three new recruits join Impact Analytical
Bringing a depth of experience to the testing laboratory
Amy Payeur joins the firm as analytical leader, working in the gas separations laboratory. A recent graduate of the University of Michigan, Payeur has a PhD in analytical chemistry in which she focused her research on gas chromatography/mass spectrometry.
Lindsay McNalley takes the role of sales account leader. She has spent the past seven years at the Dow Chemical Company, and will now focus her efforts in medical device industry sales.
Josh Lenartowicz joins the thermal and mechanical properties laboratory, working as an associate analytical technologist. Prior to this, he eight years working as a co-op student at the company.
Eric Hill, business marketing manager at Impact Analytical, said the new recruits’ expertise brings a new depth to the company’s service offerings.
You may also like
Analysis
![Cochrane review links pharma payments to prescribing practices]()
Cochrane review links pharma payments to prescribing practices
A Cochrane review of 93 studies has linked pharmaceutical industry promotional activities with less appropriate prescribing and higher prescription costs, prompting renewed calls for stronger conflict-of-interest policies and greater transparency in the UK
Manufacturing
![Patented device reinvents Solid Phase Extraction]()
Patented device reinvents Solid Phase Extraction
Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
![Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part II)]()
Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part II)
Standardised cell systems can reduce biological variability, but robust potency testing must also demonstrate accuracy, precision and linearity. ICH Q2(R2) provides the framework to establish this analytical confidence
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
![Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part I)]()
Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part I)
As biologics become increasingly complex, demonstrating consistent biological activity at lot release is essential. Yet the cell-based assays used to measure potency introduce significant challenges in standardisation, reproducibility and regulatory compliance
